Shandong Sinobioway Biomedicine Co., Ltd. (SHE:002581)
8.40
+0.40 (5.00%)
At close: Feb 27, 2026
SHE:002581 Revenue
Shandong Sinobioway Biomedicine had revenue of 141.28M CNY in the quarter ending September 30, 2025, with 35.94% growth. This brings the company's revenue in the last twelve months to 257.74M, down -36.54% year-over-year. In the year 2024, Shandong Sinobioway Biomedicine had annual revenue of 360.41M, down -16.14%.
Revenue (ttm)
257.74M
Revenue Growth
-36.54%
P/S Ratio
21.50
Revenue / Employee
541.48K
Employees
476
Market Cap
5.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 360.41M | -69.39M | -16.14% |
| Dec 31, 2023 | 429.79M | 72.71M | 20.36% |
| Jan 1, 2023 | 357.08M | -45.63M | -11.33% |
| Jan 1, 2022 | 402.71M | 125.88M | 45.47% |
| Dec 31, 2020 | 276.83M | -290.81M | -51.23% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jianmin Pharmaceutical Group | 3.18B |
| Luoxin Pharmaceuticals Group Stock | 2.49B |
| Fuan Pharmaceutical (Group) | 1.71B |
| Bide Pharmatech | 1.27B |
| Zhuhai Rundu Pharmaceutical | 1.19B |
| Nanjing Hicin Pharmaceutical | 615.39M |
| Zhongzhu Healthcare Holding Co.,Ltd | 570.62M |
| Hubei Biocause Heilen Pharmaceutical | 430.77M |